Last
Update:
December 08, 2014
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
-
POSTER
A 2-Months-off/4-Months-on HAART
Is Clinically Not Inferior to Continuous Therapy but Leads
to Unacceptable Resistance Rates in African Adults with >350
CD4/mm3 at First Interruption:
Final Results of the Trivacan Trial
C Danel, R Moh,
ML Chaix, et al
PDF Poster Abstract
-
Genetic characterization of rebounding HIV-1 after interruption of HAART in
chronic patients
with
suppressed viremia
S Rusconi, E Bulgheroni, P Citterio, et al
Abstract
-
Prevalence and predictors of treatment interruptions in a longitudinal cohort
study in women
M Gandhi, N Ameli, T Liegler, R Grant, et al
Abstract
-
Prevalence and predictors of treatment interruptions in a longitudinal cohort
study
in
women
M Gandhi, N Ameli, T Liegler, R Grant, et al
Abstract
-
A
randomized controlled trial of long term structured treatment interruption
versus intermittent
HAART
in early treated HIV infected patients
G D’Offizi, C Gioia, C Montesano, et al
Abstract
-
CTL
recognition of autologous HIV-1 variants during peak viremia after structured
treatment interruption
E G Harrer, M Bäuerle, S Bergmann, et al
Abstract
-
The
effect of structured treatment interruption on the CD8+ T-cell non-cytotoxic
antiviral response in
subjects with primary HIV infection
M S Killian, F M Hecht, J A Levy
Abstract
-
Dynamics of immunologic decline and virological rebound during treatment
interruption in chronic HIV |
disease: The CHORUS cohort
R Mera, B Most, R B Balu, J Fusco
Abstract
-
Evaluation of outcomes following structured treatment interruptions (STI)
among patients with prior nadir
CD4
>200 cells/mm³
S G Montaner, P R Harrigan, A R Toulson, et al
Abstract
-
Evaluation of outcomes following structured treatment interruptions (STI)
among patients with prior
nadir
CD4 >200 cells/mm³
J S G Montaner, P R Harrigan, A R Toulson, et al
Abstract
-
Post-clinical trial preference for CD4-guided versus continuous HAART in Thai
patients previously
randomized
to CD4-guided treatment in a structured treatment interruption trial
J Ananworanich, W Apateerapong, U Siangphoe, et al
Abstract
-
Early
savings through a strategy of CD4-guided treatment interruptions in Thailand
J Ananworanich, S Wicharuk, U Siangphoe, R Ruxrungtham, et a
Abstract
-
Metabolic parameters during long-term supervised treatment interruption
(LT-STI)
K Koppel, G Bratt, A Karlsson, E Sandstrom, et al
Abstract
-
A
multicentre study on CD4 count-guided treatment interruptions
C Mussini, A Cozzi-Lepri, V Borghi, et al
Abstract
-
Predictive factors of failure antiretroviral treatment interruption (TI) in
chronic stable HIV-infected patients
R Torres, M Cervero, J Jusdado, M Del Alamo, et al
Abstract
-
A
randomised trial of monitoring practice and structured treatment interruptions
in the management of
antiretroviral therapy in adults with HIV infection in Africa: the DART trial
A Reid, P Munderi, C Kityo, D M Gibb, et al
Abstract
-
Non-structured treatment interruption in HIV: what patients may benefit of?
H O Mingrone, N B Porteiro, E E Loiza
Abstract
-
The
FOTO Study: A pilot study of short-cycle treatment interruption, taking
antiretroviral medications
for
five days on, two days off (FOTO), for those with viral load suppression on
either PI or EFV-based
regimens.
C J Cohen, A Morris, S Bazner, et al
Abstract
-
HIV
transmission risk among patients enrolled in a large clinical trial evaluating
treatment interruption
W Burman, J Neuhaus, C Rietmeijer, et al
Abstract
-
Low-Dose Daily IL-2 combined with structured treatment interruptions (STI) did
not increase the HIV-1-
Specific T-cell responses in patients receiving HAART within 90 days after
onset primary HIV-1 Infection (
PHI)
Symptoms.
J M Miro, M Plana, F Garcia, et al
Abstract
-
Evaluation of Boosted Signal Amplification of Heat-Dissociated p24 (H-Dp24
Ag)antigen detection in
HIV-1
Chronic Infected patients during Structure Treatment Interruptions (STIs)
J G Prado, A Shintani, N Izquierdo, et al
Abstract
-
Progress report on a structured treatment interruption (STI) trial : Trivacan
ANRS 1269 trial,
Abidjan,
Côte d'Ivoire
C Danel, R Moh, S Sorho, A Anzian, et al
Abstract
-
Improvement of lipidic assestment and of lipodystrophy in HIV-experienced
patients during prolongued
antiretroviral treatment interruption (PTI)
C Martinelli, R Giuntini, S Ambu,
Abstract
-
Improvement of lipidic assestment and of lipodystrophy in HIV-experienced
patients during prolongued
|antiretroviral
treatment interruption (PTI)
C Martinelli, R Giuntini, S Ambu, et al
Abstract
|
XV
International AIDS Conference
2nd
IAS Conference
XII
International Drug Resistance Workshop
Struct
Therapy Int
Main Page
Main
New/Newsworthy
